Ajanta Pharma Announces Q1 FY 2027 Unaudited Financial Results Release and Earnings Conference Call
Ajanta Pharma Limited announced that the company will release its Q1 FY 2027 Unaudited Financial Results on July 30, 2026. The financial results will be followed by an Earnings Conference Call hosted by the leadership team to discuss the performance and address questions from participants.The Earnings Conference Call is scheduled for July 30, 2026, at 16:15 hrs IST. Participants can join the call via various international time zones, including 18:45 hrs SST/HKT, 11:45 hrs BST, and 06:45 hrs US ET.
The company provided detailed dial-in information for the conference call, which is expected to run from 16:15 to 17:15 hrs IST (the schedule allows for a one-hour duration).
Details for the Earnings Conference Call are provided below:
| Metric | Details |
|---|---|
| Date and Time | July 30, 2026, from 16:15 to 17:15 hrs IST (International timings vary) |
| Primary Access Numbers | (+91 22 6280 1542) and (+91 22 7115 8372) |
| International Toll Free Contacts | USA: 18667462133, UK: 08081011573, Hong Kong: 800964448, Singapore: 8001012045 |
The company also noted a revision to the timing of a previously scheduled Earnings Conference Call, which was revised from 4:30 p.m. (IST) to 4:15 p.m. (IST).
Following the conclusion of the conference call, Ajanta Pharma has stated that the audio playback will be available on its website within 120 minutes of the call's end.
AJANTPHARM Stock Price Movement
As of 1:53 PM, shares of Ajanta Pharma Limited are trending higher to ₹3553.5, rallying by 2.44% in live trading, propelled by strong momentum in the pharmaceutical sector. This performance sees the stock nearing its peak valuation as it pushes toward a 52-week high and processes significant volume of 141,204 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.